From: Dynamic changes of CSF sTREM2 in preclinical Alzheimer’s disease: the CABLE study
Characteristics | Stage 0 | Stage 1 | Stage 2 | SNAP | P |
---|---|---|---|---|---|
n | 242 | 148 | 70 | 199 | |
Age (years) | 60.81 ± 9.95 | 60.39 ± 10.41 | 64.19 ± 11.09 | 64.59 ± 10.28 | < 0.001 |
Gender (F/M) | 96 / 146 | 63 / 85 | 31 / 39 | 73 / 126 | 1.000 |
Education (years) | 9.96 ± 4.39 | 10.17 ± 4.20 | 9.24 ± 4.56 | 9.32 ± 4.37 | 0.188 |
APOE ε4 carriers (%) | 38 (15.70) | 22 (14.86) | 18 (25.71) | 27 (13.57) | 1.000 |
CM-MMSE score | 27.94 ± 2.25 | 27.92 ± 1.99 | 27.41 ± 2.18 | 27.61 ± 2.06 | 0.155 |
CSF biomarker | |||||
Aβ1–42 (pg/ml) | 170.41 ± 63.10 | 103.31 ± 7.26 | 102.95 ± 6.31 | 224.78 ± 139.64 | < 0.001 |
Aβ1–40 (pg/ml) | 5669.91 ± 1855.05 | 4567.68 ± 1906.91 | 7379.50 ± 2545.57 | 8493.87 ± 2982.58 | < 0.001 |
T-tau (pg/ml) | 135.72 ± 25.95 | 124.98 ± 2.55 | 262.85 ± 104.36 | 241.30 ± 88.10 | < 0.001 |
P-tau (pg/ml) | 33.18 ± 3.85 | 31.49 ± 3.87 | 46.13 ± 10.84 | 46.99 ± 11.37 | < 0.001 |
Aβ1–42/Aβ1–40 (Median, IQR) | 0.029 (0.024–0.037) | 0.024 (0.018–0.032) | 0.014 (0.011–0.018) | 0.025 (0.18–0.031) | < 0.001 |
T-tau/Aβ1–42 (Median, IQR) | 0.84 (0.69–1.03) | 1.20 (1.02–1.36) | 2.22 (1.85–3.02) | 1.13 (0.90–1.58) | < 0.001 |
P-tau/Aβ1–42 (Median, IQR) | 0.21 (0.17–0.25) | 0.31 (0.28–0.33) | 0.42 (0.39–0.51) | 0.24 (0.19–0.31) | < 0.001 |
sTREM2 (pg/ml) | 18,000.57 ± 6344.52 | 15,121.87 ± 6396.85 | 18,282.53 ± 7538.97 | 20,814.16 ± 6105.39 | < 0.001 |